RFK Jr looks to alter rare disease regulation by fast-tracking drug approvals
During an FDA panel discussion, the US health secretary prioritised easier routes to market for curative therapies.

During an FDA panel discussion, the US health secretary prioritised easier routes to market for curative therapies.
Experts predict growing pains as the life sciences sector moves to adapt to the EU AI Act.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Next-generation targeting for evolving HCP engagement
Are regulators keeping pace with AI adoption in clinical trials?
Recursion axes drug programmes to streamline pipeline
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos